Overview

Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to study the effect of nabilone (a synthetic cannabinoid)on spasticity in spinal cord injured persons.The study will be a phase 2, randomized, placebo-controlled crossover study. Each eligible subject will participate for 26 weeks.Subjects will be randomized to receive either nabilone or placebo during phase 1 of the study. Study drug will be titrated up from 0.5mg daily to a maximum of 3.0 mg daily over the first 11-week phase. Following a 4-week washout period, subjects will be crossed-over to the opposite arm for another 11 week treatment period (phase 2).
Phase:
Phase 2
Details
Lead Sponsor:
University of Manitoba
Collaborators:
Canadian Paraplegic Association
Health Sciences Centre Foundation, Manitoba
The Manitoba Spinal Cord Injury Research Fund
Treatments:
Dronabinol
Nabilone